docwirenews.com
Cure8 news brief
Why This Matters
The study suggests upadacitinib may improve both symptoms and MRI‑documented healing of perianal fistulas in Crohn’s disease, offering a potential treatment option especially for patients who have not previously received anti‑TNF therapy or who have shorter disease duration.
Who Should Pay Attention
Adults with perianal Crohn’s disease; clinicians treating fistulizing disease; patients considering JAK inhibitors after biologic exposure; researchers studying therapies for perianal fistulas.
Study Snapshot
Story typeResearch news
Evidence typeClinical study
Source depthFull source text
What To Know
This report pooled real‑world data from 10 North American centers (125 adults) treated with upadacitinib for active perianal Crohn’s disease. At a median follow‑up of about 6 months, roughly 45% had a clinical response and about 39% reached clinical remission by perianal disease activity index criteria.
Among patients with paired pelvic MRI, two‑thirds showed radiologic improvement or healing, providing objective evidence beyond symptoms. Many patients had prior anti‑TNF exposure, and the analysis found higher response rates in anti‑TNF–naïve patients and those with shorter perianal disease duration.
Hospitalizations and perianal surgeries occurred in a minority during follow‑up.
Keep In Mind
Retrospective cohort design and limited median follow‑up (~6 months) mean results are preliminary compared with randomized trials. MRI outcomes were available for a subset of patients. The article references phase III trial post‑hoc analyses and a linked journal record; this news piece summarizes those findings.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical study
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationdocwirenews.com
Indexed viaGoogle News
Source typeResearch news
PublishedJul 13, 2026, 1:44 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A Real-World Study of Upadacitinib in Anti-TNF Refractory Crohn's Disease - Dove Medical Press
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
Upadacitinib shows year-long benefit in perianal Crohn's disease
Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Upadacitinib. The original article is from msn.com.
Upadacitinib Shows Efficacy in Refractory Crohn's Disease - Medscape
This study reports that upadacitinib produced clinical responses and steroid-free remission in a majority of patients with refractory Crohn's disease at 12 weeks, which may be relevant for people who have not responded...